References

Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation

10.1001/archinternmed.2010.271 · ExternalCitation · doi-reference

Optimal Antithrombotic Regimens for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis

10.1001/jamacardio.2019.6175 · ExternalCitation · doi-reference

Rivaroxaban Monotherapy vs. Combination Therapy with Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation with Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial

10.1001/jamacardio.2022.1561 · ExternalCitation · doi-reference

Atrial cardiopathy and thrombus composition in acute ischemic stroke: Histological examination reveals insights into etiology and outcomes

10.1007/s11239-025-03155-6 · ExternalCitation · doi-reference

Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction

10.1016/j.ahj.2016.01.021 · ExternalCitation · doi-reference

Association of CHA(2)DS(2)-VASc and HAS-BLED to frailty and frail outcomes: From the TREAT-AF study

10.1016/j.ahj.2023.03.015 · ExternalCitation · doi-reference

Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy

10.1016/j.amjcard.2008.08.021 · ExternalCitation · doi-reference

Procedural Complexity and Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention

10.1016/j.amjcard.2025.12.012 · ExternalCitation · doi-reference

Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations

10.1016/j.ejim.2022.04.023 · ExternalCitation · doi-reference

Trial sequential analysis methodology for interpreting meta-analytical findings

10.1016/j.ejim.2023.12.029 · ExternalCitation · doi-reference

Assessment of Noninferiority Margins in Cardiovascular Medicine Trials

10.1016/j.jacadv.2024.101021 · ExternalCitation · doi-reference

Stroke Prevention with Oral Anticoagulants in High-Risk Atrial Fibrillation in an Aging Population

10.1016/j.jacadv.2025.101757 · ExternalCitation · doi-reference

The myth of the “vulnerable plaque”: Transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment

10.1016/j.jacc.2014.11.041 · ExternalCitation · doi-reference

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial

10.1016/j.jacc.2015.02.050 · ExternalCitation · doi-reference

Outcomes of Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

10.1016/j.jacc.2016.05.085 · ExternalCitation · doi-reference

Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI

10.1016/j.jacc.2017.08.018 · ExternalCitation · doi-reference

DAPT Study Investigators. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

10.1016/j.jacc.2017.09.011 · ExternalCitation · doi-reference

Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review

10.1016/j.jacc.2019.05.016 · ExternalCitation · doi-reference

Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week

10.1016/j.jacc.2019.08.1031 · ExternalCitation · doi-reference

Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes with or Without PCI

10.1016/j.jacc.2020.05.031 · ExternalCitation · doi-reference

2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or with Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee

10.1016/j.jacc.2020.09.011 · ExternalCitation · doi-reference

Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review

10.1016/j.jacc.2021.10.037 · ExternalCitation · doi-reference

Patients with Atrial Fibrillation and PCI or ACS: Does Predicted Risk Matter?

10.1016/j.jacc.2021.11.034 · ExternalCitation · doi-reference

Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke: JACC State-of-the-Art Review

10.1016/j.jacc.2023.07.025 · ExternalCitation · doi-reference

10.1016/j.jacc.2023.08.017

10.1016/j.jacc.2023.08.017 · ExternalCitation · doi-reference

Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison from AUGUSTUS

10.1016/j.jacc.2024.06.022 · ExternalCitation · doi-reference

Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights from AUGUSTUS

10.1016/j.jacc.2024.10.125 · ExternalCitation · doi-reference

Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials

10.1016/j.jacc.2024.12.030 · ExternalCitation · doi-reference

Perspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline

10.1016/j.jacc.2025.04.045 · ExternalCitation · doi-reference

Targeting Inflammation After Acute Myocardial Infarction

10.1016/j.jacc.2025.07.064 · ExternalCitation · doi-reference

Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the PIONEER AF-PCI Trial

10.1016/j.jcin.2017.11.009 · ExternalCitation · doi-reference

Renal Function and Outcomes with Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

10.1016/j.jcin.2019.05.050 · ExternalCitation · doi-reference

Tug of War Between Dual and Triple Antithrombotic Therapy in Atrial Fibrillation/PCI Patients with CKD

10.1016/j.jcin.2019.06.032 · ExternalCitation · doi-reference

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

10.1016/j.jcin.2021.02.022 · ExternalCitation · doi-reference

Rivaroxaban Monotherapy in Patients with Atrial Fibrillation After Coronary Stenting: Insights from the AFIRE Trial

10.1016/j.jcin.2021.07.045 · ExternalCitation · doi-reference

Short Dual Antiplatelet Therapy in High Bleeding Risk Patients: 1 Month or 3 Months?

10.1016/j.jcin.2023.08.037 · ExternalCitation · doi-reference

Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions

10.1016/j.jcin.2024.08.022 · ExternalCitation · doi-reference

The Missing Dimension of Risk: From High-Risk Patients to High-Risk Periods

10.1016/j.jcin.2026.06.008 · ExternalCitation · doi-reference

Relevance of High Bleeding Risk and Postdischarge Bleeding in Patients Undergoing Percutaneous Coronary Intervention

10.1016/j.mayocp.2024.09.010 · ExternalCitation · doi-reference

10.1016/s0140-6736(06)68845-4

10.1016/s0140-6736(06)68845-4 · ExternalCitation · doi-reference

Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis

10.1016/s0140-6736(12)60324-9 · ExternalCitation · doi-reference

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial

10.1016/s0140-6736(12)62177-1 · ExternalCitation · doi-reference

Stroke prevention in atrial fibrillation

10.1016/s0140-6736(16)31257-0 · ExternalCitation · doi-reference

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial

10.1016/s0140-6736(19)31872-0 · ExternalCitation · doi-reference

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): A multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial

10.1016/s0140-6736(26)00665-3 · ExternalCitation · doi-reference

10.1038/s41591-026-04629-7

10.1038/s41591-026-04629-7 · ExternalCitation · doi-reference

10.1055/a-2862-6563

10.1055/a-2862-6563 · ExternalCitation · doi-reference

The Conundrum Surrounding Racial Differences on Ischaemic and Bleeding Risk with Dual Anti-Platelet Therapy

10.1055/s-0038-1676612 · ExternalCitation · doi-reference

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

10.1056/nejm199604253341702 · ExternalCitation · doi-reference

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators

10.1056/nejm199812033392303 · ExternalCitation · doi-reference

Refining Antithrombotic Therapy for Atrial Fibrillation and Acute Coronary Syndromes or PCI

10.1056/nejme1902214 · ExternalCitation · doi-reference

10.1056/nejmoa0901301

10.1056/nejmoa0901301 · ExternalCitation · doi-reference

Dabigatran versus warfarin in patients with atrial fibrillation

10.1056/nejmoa0905561 · ExternalCitation · doi-reference

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

10.1056/nejmoa1009638 · ExternalCitation · doi-reference

Apixaban versus warfarin in patients with atrial fibrillation

10.1056/nejmoa1107039 · ExternalCitation · doi-reference

Edoxaban versus warfarin in patients with atrial fibrillation

10.1056/nejmoa1310907 · ExternalCitation · doi-reference

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

10.1056/nejmoa1611594 · ExternalCitation · doi-reference

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

10.1056/nejmoa1708454 · ExternalCitation · doi-reference

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

10.1056/nejmoa1817083 · ExternalCitation · doi-reference

Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease

10.1056/nejmoa1904143 · ExternalCitation · doi-reference

Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease

10.1056/nejmoa2407362 · ExternalCitation · doi-reference

Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation

10.1056/nejmoa2507532 · ExternalCitation · doi-reference

Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents

10.1056/nejmoa2512091 · ExternalCitation · doi-reference

Management of Antithrombotic Therapy after Acute Coronary Syndromes

10.1056/nejmra1607714 · ExternalCitation · doi-reference

Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation

10.1080/07853890802089786 · ExternalCitation · doi-reference

Differences in coronary artery disease and outcomes of percutaneous coronary intervention with drug-eluting stents in women and men

10.1080/14779072.2021.1902806 · ExternalCitation · doi-reference

Antithrombotic therapy after left atrial appendage occlusion

10.1080/14779072.2025.2486154 · ExternalCitation · doi-reference

Stent type selection in high bleeding risk patients

10.1080/17434440.2024.2439028 · ExternalCitation · doi-reference

Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: A collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials

10.1093/ehjcvp/pvaa116 · ExternalCitation · doi-reference

Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials

10.1093/ehjcvp/pvac065 · ExternalCitation · doi-reference

Pharmacological and clinical appraisal of factor XI inhibitor drugs

10.1093/ehjcvp/pvae002 · ExternalCitation · doi-reference

Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: A pre-specified analysis of the ENTRUST-AF PCI trial

10.1093/eurheartj/ehaa617 · ExternalCitation · doi-reference

Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: Risk and timing

10.1093/eurheartj/ehac587 · ExternalCitation · doi-reference

Dual antiplatelet therapy in patients at high bleeding risk: Less is more-more or less

10.1093/eurheartj/ehac713 · ExternalCitation · doi-reference

2023 ESC Guidelines for the management of acute coronary syndromes

10.1093/eurheartj/ehad191 · ExternalCitation · doi-reference

2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

10.1093/eurheartj/ehae176 · ExternalCitation · doi-reference

2024 ESC Guidelines for the management of chronic coronary syndromes

10.1093/eurheartj/ehae177 · ExternalCitation · doi-reference

CHA2DS2-VASc or a non-sex score (CHA2DS2-VA) for stroke risk prediction in atrial fibrillation: Contemporary insights and clinical implications

10.1093/eurheartj/ehae540 · ExternalCitation · doi-reference

Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: Insights from the ARISTOTLE trial

10.1093/eurheartj/eht445 · ExternalCitation · doi-reference

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: A subgroup analysis from the RE-DUAL PCI trial

10.1093/eurheartj/ehz059 · ExternalCitation · doi-reference

Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials

10.1093/eurheartj/ehz732 · ExternalCitation · doi-reference

Therapeutic uncertainties: First finding of atrial fibrillation in acute coronary syndrome

10.1093/eurheartjsupp/suac072 · ExternalCitation · doi-reference

Factor XI inhibitors and atrial fibrillation: Imminent breakthrough or false start?

10.1093/eurheartjsupp/suaf015 · ExternalCitation · doi-reference

Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society

10.1093/europace/euac020 · ExternalCitation · doi-reference

Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease

10.1155/2022/5905022 · ExternalCitation · doi-reference

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: The full anticoagulation versus aspirin and ticlopidine (fantastic) study

10.1161/01.cir.98.16.1597 · ExternalCitation · doi-reference

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)

10.1161/01.cir.98.20.2126 · ExternalCitation · doi-reference

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

10.1161/cir.0000000000001328 · ExternalCitation · doi-reference

2026 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association

10.1161/cir.0000000000001412 · ExternalCitation · doi-reference

Atrial Fibrillation Burden and Short-Term Risk of Stroke: Case-Crossover Analysis of Continuously Recorded Heart Rhythm from Cardiac Electronic Implanted Devices

10.1161/circep.114.003057 · ExternalCitation · doi-reference

Postdischarge Bleeding After Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction: Insights from the HMO Research Network-Stent Registry

10.1161/circinterventions.115.003519 · ExternalCitation · doi-reference

Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention

10.1161/circinterventions.118.007604 · ExternalCitation · doi-reference

Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis from the REDUAL PCI Trial

10.1161/circinterventions.119.008349 · ExternalCitation · doi-reference

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

10.1161/circulationaha.112.115386 · ExternalCitation · doi-reference

Open-Label Randomized Trial Comparing Oral Anticoagulation with and Without Single Antiplatelet Therapy in Patients with Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation

10.1161/circulationaha.118.036768 · ExternalCitation · doi-reference

Stroke Risk as a Function of Atrial Fibrillation Duration and CHA(2)DS(2)-VASc Score

10.1161/circulationaha.119.041303 · ExternalCitation · doi-reference

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial

10.1161/circulationaha.119.043308 · ExternalCitation · doi-reference

Stent Thrombosis in Patients with Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial

10.1161/circulationaha.119.044584 · ExternalCitation · doi-reference

Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients with Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights from AUGUSTUS

10.1161/circulationaha.120.046534 · ExternalCitation · doi-reference

Antithrombotic Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update

10.1161/circulationaha.120.050438 · ExternalCitation · doi-reference

Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk with or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial

10.1161/circulationaha.121.056680 · ExternalCitation · doi-reference

Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention

10.1161/circulationaha.124.072009 · ExternalCitation · doi-reference

Safety and Efficacy of Double Antithrombotic Therapy with Non–Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis

10.1161/jaha.120.017212 · ExternalCitation · doi-reference

Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239,234 Patients During 2005 to 2018 in the United States

10.1161/jaha.121.022198 · ExternalCitation · doi-reference

Antithrombotic Management in AF Patients Following Percutaneous Coronary Intervention: A European Perspective

10.15420/icr.2021.30 · ExternalCitation · doi-reference

In-hospital outcomes in nonagenarian patients undergoing primary percutaneous coronary intervention

10.23736/s2724-5683.22.06167-1 · ExternalCitation · doi-reference

Future of factor XI inhibitors in cardiovascular practice

10.23736/s2724-5683.23.06474-8 · ExternalCitation · doi-reference

10.3390/jcdd12090344

10.3390/jcdd12090344 · ExternalCitation · doi-reference

10.3390/jcm13010098

10.3390/jcm13010098 · ExternalCitation · doi-reference

10.3390/jcm14228079

10.3390/jcm14228079 · ExternalCitation · doi-reference

10.3390/jcm15114248

10.3390/jcm15114248 · ExternalCitation · doi-reference

Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: A post hoc analysis of the randomised RE-DUAL PCI trial

10.4244/eij-d-20-00799 · ExternalCitation · doi-reference

Mortality after bleeding versus myocardial infarction in coronary artery disease: A systematic review and meta-analysis

10.4244/eij-d-20-01197 · ExternalCitation · doi-reference

Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition

10.4244/eij-d-21-00181 · ExternalCitation · doi-reference

Dual versus triple antithrombotic therapy after percutaneous coronary intervention: The prospective multicentre WOEST 2 Study

10.4244/eij-d-21-00703 · ExternalCitation · doi-reference

Antithrombotic therapy for stable coronary artery disease and atrial fibrillation in patients with and without revascularisation: The AFIRE trial

10.4244/eij-d-23-00396 · ExternalCitation · doi-reference

Antithrombotic therapy in patients with atrial fibrillation undergoing PCI remains a moving target, yet with a clearer direction!

10.4244/eij-e-22-00004 · ExternalCitation · doi-reference